ProMetic Life Sciences Inc. (PLI.TO) Monday said it has granted manufacturing rights to Hematech Biotherapeutics Inc. of a plasma-derived biopharmaceutical product targeting a rare medical condition using ProMetic's proprietary PPPS.
Hematech will pay ProMetic $10 million for the orphan drug development program, a $1 million upfront payment followed by $9 million staged payments.
The drug would be manufactured in ProMetic's Laval facility and in Hematech's planned facility in Taiwan.
Following the completion of clinical trials and regulatory approval, the drug will be commercialized jointly by ProMetic and Hematech on a global basis, excluding China, with both parties sharing profits equally.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.